These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26813357)

  • 1. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
    Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
    N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
    Van Damme P; Bouillette-Marussig M; Hens A; De Coster I; Depuydt C; Goubier A; Van Tendeloo V; Cools N; Goossens H; Hercend T; Timmerman B; Bissery MC
    Clin Cancer Res; 2016 Jul; 22(13):3238-48. PubMed ID: 27252412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
    van Poelgeest MI; van Seters M; van Beurden M; Kwappenberg KM; Heijmans-Antonissen C; Drijfhout JW; Melief CJ; Kenter GG; Helmerhorst TJ; Offringa R; van der Burg SH
    Clin Cancer Res; 2005 Jul; 11(14):5273-80. PubMed ID: 16033846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia.
    Todd RW; Steele JC; Etherington I; Luesley DM
    Gynecol Oncol; 2004 Jan; 92(1):167-74. PubMed ID: 14751153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
    Welters MJ; Kenter GG; de Vos van Steenwijk PJ; Löwik MJ; Berends-van der Meer DM; Essahsah F; Stynenbosch LF; Vloon AP; Ramwadhdoebe TH; Piersma SJ; van der Hulst JM; Valentijn AR; Fathers LM; Drijfhout JW; Franken KL; Oostendorp J; Fleuren GJ; Melief CJ; van der Burg SH
    Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11895-9. PubMed ID: 20547850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
    Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
    Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
    Soong RS; Song L; Trieu J; Knoff J; He L; Tsai YC; Huh W; Chang YN; Cheng WF; Roden RB; Wu TC; Trimble CL; Hung CF
    Clin Cancer Res; 2014 Nov; 20(21):5456-67. PubMed ID: 24893628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.
    Daayana S; Elkord E; Winters U; Pawlita M; Roden R; Stern PL; Kitchener HC
    Br J Cancer; 2010 Mar; 102(7):1129-36. PubMed ID: 20234368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review.
    de Witte CJ; van de Sande AJ; van Beekhuizen HJ; Koeneman MM; Kruse AJ; Gerestein CG
    Gynecol Oncol; 2015 Nov; 139(2):377-84. PubMed ID: 26335596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
    de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
    Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.
    Bakker NAM; Rotman J; van Beurden M; Zijlmans HJM; van Ruiten M; Samuels S; Nuijen B; Beijnen J; De Visser K; Haanen J; Schumacher T; de Gruijl TD; Jordanova ES; Kenter GG; van den Berg JH; van Trommel NE
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.